Skip to content

Study to evaluate the efficacy of conventional topical therapy for atopic dermatitis based on Filaggrin-gene mutations

Study to evaluate the efficacy of conventional topical therapy for atopic dermatitis based on Filaggrin-gene mutations - Study to evaluate the efficacy of conventional topical therapy for atopic dermatitis based on Filaggrin-gene mutations

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000010009
Enrollment
30
Registered
2013-02-12
Start date
2012-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

Applying Split-plot design, multiple factors are randomized. 4 sites of each cubital fossa and popliteal fossa are used as a independent site respectively. 1st factor is presence or absence of filagg

Sponsors

Hokkaido University Graduate School of Medicine, Department of Dermatology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients of atopic dermatitis diagnosed by the diagnostic criteria for atopic dermatitis by Hanifin & Rajika, U.K.Working Party or Japan Society of Dermatology. Patients with moderate to severe skin lesions.

Exclusion criteria

Exclusion criteria: Patients who have obviously infected lesion in the popliteal and cubital fossa. Patients who have atrophy or telangiectasia in the popliteal and cubital skin caused by the topical steroid application. Patients who has serious underlying disease. Patients who had participated in other clinical trials within 6 months.

Design outcomes

Primary

MeasureTime frame
Amount of change in the score of intensity which is used in SCORAD. 6 criteria include erythema, edema/ papulation, oozing/ crusting, excoriation and lichenification which is scored by 0 to 3 points respectively.

Secondary

MeasureTime frame
TEWL SC hydration VAS of itch Evaluation of presence or absence of flare-ups in the sites which are/ are not apllied moisturizer for the sites without eruption.

Countries

Japan

Contacts

Public ContactOsamu Mizuno

Hokkaido University Hospital Department of Dermatology

011-706-7387

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026